COMPASS Pathways (CMPS) Scheduled to Post Quarterly Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 1st. Analysts expect COMPASS Pathways to post earnings of ($0.53) per share for the quarter.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

COMPASS Pathways Stock Down 4.5 %

CMPS stock opened at $6.94 on Thursday. The company’s 50 day moving average price is $6.93 and its 200 day moving average price is $8.66. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23. COMPASS Pathways has a fifty-two week low of $5.01 and a fifty-two week high of $12.75. The firm has a market capitalization of $474.56 million, a price-to-earnings ratio of -2.93 and a beta of 2.27.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CMPS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Friday, June 21st. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a report on Monday, May 13th. Morgan Stanley began coverage on COMPASS Pathways in a report on Monday, April 1st. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Royal Bank of Canada began coverage on COMPASS Pathways in a report on Tuesday. They issued an “outperform” rating and a $23.00 price target for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $43.33.

Insider Activity

In other news, major shareholder George Jay Goldsmith sold 9,621 shares of the stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $8.29, for a total value of $79,758.09. Following the completion of the sale, the insider now directly owns 3,966,052 shares of the company’s stock, valued at $32,878,571.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.25% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.